For the quarter ending 2026-03-31, ELOX had $1,578K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -3,754 |
| Stock-based compensation | 46 |
| Amortization of debt discount | 7 |
| Gain on extinguishment of accrued interest | 56 |
| Imputed interest expense on 2025 bridge loans | 0 |
| License fee receivable | 0 |
| Unbilled receivable | 0 |
| Prepaid expenses and other current assets | 1,655 |
| Accounts payable | 315 |
| Accrued expenses | -377 |
| Accrued interest | -21 |
| Net cash (used in) provided by operating activities | -5,453 |
| Proceeds from issuance of pre-funded warrants under the coastlands and domicilium securities purchase agreements, net of issuance costs | 6,991 |
| Repayment of term loan principal | 0 |
| Proceeds from debt financing obligations | 0 |
| Exercise of stock options | 40 |
| Net cash provided by (used in) financing activities | 7,031 |
| Increase in cash, cash equivalents and restricted cash | 1,578 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 4,791 |
| Cash, cash equivalents and restricted cash at the end of the period | 6,369 |
Eloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals, Inc. (ELOX)